Volume 4.32 | Aug 20

Pancreatic Cell News 4.32 August 20, 2013
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
Retinoblastoma Tumor Suppressor Protein in Pancreatic Progenitors Controls α- and β-Cell Fate
Investigators showed that deletion of murine retinoblastoma tumor suppressor protein (Rb) during embryogenesis in islet progenitors leads to an increase in the neurogenin 3-expressing precursor cell population, which persists in the postnatal period and is associated with increased β-cell mass in adults. [Proc Natl Acad Sci USA] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Implanted Islets in the Anterior Chamber of the Eye Are Prone to Autoimmune Attack in a Mouse Model of Diabetes
Scientists examined the anterior chamber of the eye as a potential islet transplant site, and also evaluated whether in vivo imaging of the islets transplanted in the eye could enable real-time visualization of autoimmune processes underway in the pancreas. [Diabetologia] Abstract

Rhein Protects Pancreatic β-Cells from Dynamin-Related Protein-1-Mediated Mitochondrial Fission and Cell Apoptosis under Hyperglycemia
Rhein, an anthraquinone compound isolated from rhubarb, has been shown to improve glucose metabolism disorders in diabetic mice. The authors demonstrated that Rhein can protect the pancreatic β-cells against hyperglycemia-induced cell apoptosis through stabilizing mitochondrial morphology. [Diabetes] Abstract

Multimodal Function of the Sweet Taste Receptor Expressed in Pancreatic β-Cells: Generation of Diverse Patterns of Intracellular Signals by Sweet Agonists
The sweet taste receptor is expressed in the taste bud and is activated by numerous sweet molecules with diverse chemical structures. It is, however, not known whether these sweet agonists induce a similar cellular response in target cells. Using MIN6 cells, a pancreatic β-cell line expressing endogenous sweet taste receptor, the authors addressed this question by monitoring changes in cytoplasmic Ca2+ and cAMP induced by four sweet taste receptor agonists. [Endocr J] Abstract | Full Article

Grb10 Inhibits Glucose-Stimulated Insulin Release from Pancreatic β-Cells Associated with Suppression of Insulin/IGF-1 Signaling Pathway
Scientists demonstrated that growth receptor binding protein 10 (Grb10) is an important negative regulator of insulin/IGF-1 signaling in pancreatic β-cells and a potential target to improve β-cell function. [Clin Exp Pharmacol Physiol] Abstract


Flavonoid Apigenin Modified Gene Expression Associated with Inflammation and Cancer and Induced Apoptosis in Human Pancreatic Cancer Cells through Inhibition of GSK-3β/NF-κB Signaling Cascade
Scientists examined the inhibitory effects of citrus fruit bioactive compounds on BxPC-3 and PANC-1 human pancreatic cancer cells, focusing on the antiproliferative mechanism of action of the flavonoid apigenin related to the glycogen synthase kinase-3β/nuclear factor kappa B signaling pathway. [Mol Nutr Food Res] Abstract | Press Release

Increased B Cell-Activating Factor Promotes Tumor Invasion and Metastasis in Human Pancreatic Cancer
In this study, clinical evidence of increased B cell-activating factor (BAFF) levels in patients with pancreatic ductal adenocarcinoma (PDAC) was obtained, and the roles and mechanisms of BAFF in PDAC were clarified in human tissues of PDAC and from in vitro data of PDAC cell lines. [PLoS One] Full Article

Digalloylresveratrol, a Novel Resveratrol Analog Inhibits the Growth of Human Pancreatic Cancer Cells
The authors investigated the effects of digalloylresveratrol (DIG) in the human AsPC-1 and BxPC-3 pancreatic adenocarcinoma cell lines. Treatment with DIG dose-dependently attenuated cells in the S phase of the cell cycle and led to a significant depletion of the dATP pool in AsPC-1 cells. [Invest New Drugs] Abstract

High Glucose Activates the Alternative Angiotensin‑Converting Enzyme2/Angiotensin (Ang)‑(1‑7)/Mas and APN/Ang IV/IRAP RAS Axes in Pancreatic β‑Cells
In this study, using the BRIN‑BD11 rat insulinoma cell line, researchers examined the basal expression levels of components of classical and alternative renin‑angiotensin system (RAS) axes and investigated the effects of normal and elevated glucose concentrations on their expression and/or enzymatic activity by means of reverse transcription quantitative PCR, immunoblot analysis and enzymatic activity assays. [Int J Mol Med] Abstract

Take the 'if' out of 'diff': Reduce variability when differentiating to endothelial cells
Immune Monitoring of Islet and Pancreas Transplant Recipients
This review describes the tools established and validated to monitor immune correlates of auto- and alloreactivity that associate with clinical outcome and identifies challenges that current immunosuppression strategies trying to preserve islet graft function face. [Curr Diab Rep] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
Pharmacy Researcher Fights Cancer, Pain with New Drug
Dai Lu, Ph.D., assistant professor of pharmaceutical sciences at the Texas A&M Health Science Center Irma Lerma Rangel College of Pharmacy, has been working to find new types of chemotherapeutic drugs that both kill pancreatic cancer and suppress the cancer pain at the same time by targeting a special G-protein coupled receptor that belongs to the biological system responsible for cannabis effects. [Texas A&M Health Science Center] Press Release

Diabetes & Obesity Center Wins Second Multimillion-Dollar NIH Grant
The University of Louisville’s Diabetes and Obesity Center has received a five-year $11.25 million Center of Biomedical Research Excellence (COBRE) grant from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH). A five-year COBRE grant funded establishment of the center in 2008. The center’s ultimate goal is to discover new and effective means for preventing and treating diabetes and obesity. [University of Louisville] Press Release

Montefiore Medical Center Joins as a Collaborator on Precision Biologics Phase IIB Pancreatic Cancer Trial
Precision Biologics announced the addition of Montefiore Medical Center, Bronx, NY, as a collaborator on its ongoing Phase IIB study designed to evaluate the efficacy of combining NPC-1C its lead therapeutic compound, with the chemotherapy drug Gemcitabine. [Precision Biologics Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 7th International Conference on Advanced Technologies & Treatments for Diabetes
February 5-8, 2013
Vienna, Austria

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Postdoctoral Position – Differentiation of Human Pancreatic Endocrine Precursor Cells to Beta-Cells (AstraZeneca)

NEW Postdoctoral Fellow – Pancreatic Beta Cell Regeneration and Survival (Oklahoma Medical Research Foundation)

Postdoctoral Research Associate – Diabetes and Molecular Endocrinology (University of Illinois)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Molecular Mechanisms of Pancreatic Beta Cell Dysfunction (Université Libre de Bruxelles)

Research Associate – Pancreatic Cancer (Fred Hutchinson Cancer Research Center)

Senior Scientist – Pancreas Development (AstraZeneca)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

PhD Positions – Molecular Mechanisms Controlling Acinar Cell Proliferation (University Hospital Zuerich)

Postdoctoral Researcher (The University of Texas Health Science Center at San Antonio)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pancreatic Cell News: Archives | Events | Contact Us